In Brief: SensorMedics
This article was originally published in The Gray Sheet
SensorMedics: Plans to meet with FDA in September to discuss civil penalty actions pending against the company. The firm intends to argue for waiver of proposed penalties totaling $2 mil. SensorMedics says FDA's charges should be dropped because the nine devices originally cited as violating premarket requirements no longer are on the market, having been replaced by next-generation products. In addition, the firm maintains that modifications it made to its devices were not subject to 510(k) requirements because they did not affect safety and effectiveness. Earlier this year, FDA waived penalties against Lexicor, citing corrective actions the company had taken and the firm's inability to pay the proposed fines ("The Gray Sheet" Aug. 12, p. 6)...
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.